Zobrazeno 1 - 10
of 80
pro vyhledávání: '"Sezai VATANSEVER"'
Publikováno v:
European Journal of Breast Health, Vol 19, Iss 2, Pp 128-133 (2023)
Objective:The aim was to assess the prognostic variables in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer patients receiving lapatinib plus capecitabine.Materials and Methods:Retrospective data on HER2-positive met
Externí odkaz:
https://doaj.org/article/82be6058db504093bd5493194317ce8d
Autor:
Ali Yılmaz ALTAY, Melek BÜYÜK, İlker ÖZGÜR, Ali Fuat Kaan GÖK, Bilger ÇAVUŞ, Esra AYDIN, Sezai VATANSEVER, Mine GÜLLÜOĞLU
Publikováno v:
Türk Patoloji Dergisi, Vol 37, Iss 3, Pp 203-211 (2021)
Objective: Metastatic involvement of the stomach is a rare event. Our aim in this study was to document the clinicopathological findings in patients with gastric metastases and find out if there are any potentially significant features to be used in
Externí odkaz:
https://doaj.org/article/ce419f1ae67f4669833d6b73910f94bb
Publikováno v:
Insights into Imaging, Vol 12, Iss 1, Pp 1-12 (2021)
Abstract Background Standardized response criteria for evaluating patients radiological imaging have an essential role in oncological management. Immunotherapy, using immune checkpoint inhibitors (ICIs), including drugs targeting cytotoxic T-lymphocy
Externí odkaz:
https://doaj.org/article/e5b42f00c5ca47dfae4afe41c69db11d
Autor:
Rumeysa Ciftci, Faruk Tas, Elif Bilgin, Serkan Keskin, Ibrahim Yildiz, Derya Duranyildiz, Pınar Saip, Hasan Karanlik, Sezai Vatansever
Publikováno v:
Journal of Oncological Sciences, Vol 2, Iss 1, Pp 7-11 (2016)
Background: The protease-activated receptor 1 (PAR1) is associated with increased invasiveness of breast cancer (BC) cell lines and its overexpression is significantly correlated with advanced stage and poor prognosis. The aim of this study was to de
Externí odkaz:
https://doaj.org/article/6d785d2932ce4e0289a3d27a77a70f0e
Autor:
Izzet Dogan, Nijat Khanmammadov, Melin Aydan Ahmed, Anıl Yıldız, Pinar Saip, Adnan Aydiner, Sezai Vatansever
Publikováno v:
Clinical Cancer Investigation Journal. 11:25-29
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ea9fadbf9aea02a9864a59c5996670f
https://doi.org/10.51847/87n2fddtb1
https://doi.org/10.51847/87n2fddtb1
Autor:
Izzet Dogan, Nijat Khanmammadov, Melin Aydan Ahmed, Anıl Yıldız, Pinar Saip, Adnan Aydiner, Sezai Vatansever
Publikováno v:
Clinical Cancer Investigation Journal. 11:5-9
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9453e11ca691491d1a713675decc7d7e
https://doi.org/10.51847/rvqewyffbi
https://doi.org/10.51847/rvqewyffbi
Autor:
Sezai Vatansever, Naziye Ak
Publikováno v:
Journal of Clinical Pharmacy and Therapeutics. 46:1787-1791
What is known and objective Patients with ovarian cancer have not benefited substantially from immunotherapy. We report a case of ovarian cancer, however, that responded well to the programmed cell death-ligand 1 inhibitor atezolizumab. Case summary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a56623313d6cefeab46309113a44631
https://doi.org/10.1111/jcpt.13364
https://doi.org/10.1111/jcpt.13364
Autor:
Özlem Özdemir, Baha Zengel, Yaşar Yildiz, Basak Oyan Uluç, Devrim Cabuk, Ercan Ozden, Derya Kivrak Salim, Semra Paydas, Atakan Demir, Omer Diker, Kezban Nur Pilanci, Özlem Uysal Sönmez, Sezai Vatansever, Izzet Dogan, Ahmet Gulmez, Burcu Cakar, Pinar Gursoy, Mahmut Emre Yildirim, Murat Ayhan, Nuri Karadurmus, Musa Baris Aykan, Gökcen Tugba Cevik, Teoman Sakalar, Ilhan Hacibekiroglu, Burcu Belen Gülbagci, Murat Dincer, Duygu Bayir Garbioglu, Yasemin Kemal, Erdinc Nayir, Halil Taskaynatan, Mesut Yilmaz, Okan Avci, Murat Sari, Ezgi Coban, Muhammed Mustafa Atci, Selin Aktürk Esen, Tugba Akin Telli, Fatih Karatas, Ali Inal, Hacer Demir, Nurhan Onal Kalkan, Cengiz Yilmaz, Funda Tasli, Ahmet Alacacioglu
In our study, we aimed to evaluate the pathological response rates and side effect profile of adding pertuzumab to the treatment of HER2+ locally advanced, inflammatory, or early-stage breast cancer. This study was conducted by the Turkish Oncology G
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::934c684ccacc5bd283fae448009bb29f
https://hdl.handle.net/11454/77368
https://hdl.handle.net/11454/77368
Autor:
Salim Demirci, Hakan Akbulut, Dilsa Mizrak Kaya, Güngör Utkan, İlker Özgür, Izzet Dogan, Sezai Vatansever, Emre Yekedüz, Yuksel Urun
Publikováno v:
Journal of gastrointestinal cancer. 53(4)
AIM To evaluate the prognostic role of the systemic immune-inflammation index (SII) in patients with operable gastric cancer. METHODS We assessed 354 patients with operable gastric cancer from tertiary centers in Turkey. SII was calculated by followi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58576076248c9f55491fe577ef6dab87
https://pubmed.ncbi.nlm.nih.gov/34845631
https://pubmed.ncbi.nlm.nih.gov/34845631
Autor:
Emre Yekedüz, İzzet Doğan, Dılşa Mızrak Kaya, İlker Özgür, Güngör Utkan, Sezai Vatansever, Salim Demirci, Hakan Akbulut, Yüksel Ürün
Aim To evaluate the prognostic role of the systemic immune-inflammation index (SII) in patients with operable gastric cancer. Methods We assessed 354 patients with operable gastric cancer from tertiary centers in Turkey. SII was calculated by followi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e990624ada482b0bf9e81736b832641
https://doi.org/10.21203/rs.3.rs-1042125/v1
https://doi.org/10.21203/rs.3.rs-1042125/v1